Company
Biogen
127 published works
The Law and Other Anomalies
Biogen and Boston’s Life Science Prominence
Chris Viehbacher, CEO of Boston biotech giant Biogen, believes that greater Boston has the premier gathering of scientists in medicine in the world. Addressing today’s gathering of the Boston Chamber…
Big Molecule Watch
Harrow Re-Launches BYOOVIZ (ranibizumab-nuna) in the United States
By Grace Truong
On July 1, 2026, Harrow announced the commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS (ranibizumab). BYOOVIZ was developed by Samsung Bioepis Co., Ltd. (“Samsung Bioepis”). BYOOVIZ was…
Big Molecule Watch
Sandoz Launches Natalizumab Biosimilar
On November 17, 2025, Sandoz announced the launch of TYRUKO® (natalizumab-sztn) in the United States as the first and only biosimilar for the treatment of relapsing forms of multiple sclerosis. TYRUKO® was approved…
Big Molecule Watch
Biogen Ordered to Pay Genentech $88.3 Million in Past Royalties on Cabilly Patents
On September 30, 2025, the U.S. District Court for the Northern District of California ordered Biogen MA, Inc. (“Biogen”) to pay Genentech, Inc. (“Genentech”) $88,348,123 in unpaid royalties plus interest.…
Big Molecule Watch
Harrow Enters Agreement to Commercialize Samsung Bioepis’s Ophthalmology Biosimilars Following Biogen’s Exit
On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S. commercial rights to two of Samsung Bioepis’s biosimilars, BYOOVIZ®…
Inside Class Actions
Claims that Drug Manufacturer Paid PBMs to Disrupt Operation of State Generic Substitution Laws not Viable, Says Illinois Court
On June 25, an Illinois federal court dismissed an antitrust class action that alleged that branded drug manufacturer Biogen harmed competition by paying Pharmacy Benefit Managers (“PBMs”) not to promote…
Big Molecule Watch
Biogen Files Suit Against Neurimmune Over Rights to Bispecific Antibody
On May 13, 2025, Biogen Inc. and Biogen MA Inc. (“Biogen”) filed a Complaint for Declaratory Judgment and Permanent Injunctive Relief against Neurimmune Holding AG and Neurimmune SubOne AG (“Neurimmune”)…
Big Molecule Watch
Are Reference Product Sponsors Asserting More Patents in BPCIA Litigation?
On October 24, 2014, Amgen initiated the first litigation under the Biologics Price Competition and Innovation Act (“BPCIA”), asserting infringement of two patents. Over the last two calendar years, Amgen,…
Big Molecule Watch
European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar
On November 18, 2024, Samsung Bioepis announced that the European Commission (EC) has approved its aflibercept biosimilar, OPUVIZ. Referencing Regeneron’s biosimilar product EYLEA, OPUVIZ is a 40 mg/mL solution for…
Big Molecule Watch
Biogen’s TOFIDENCE (tocilizumab) Approved in the EU
This week, Biogen announced that the European Commission has approved TOFIDENCE, a tocilizumab biosimilar referencing Roche’s ROACTEMRA. TOFIDENCE was approved by the FDA in September 2023. TOFIDENCE is an intravenous…